Evaluating the Safety of Netarsudil
Francis Mah, MD, joins Neda Shamie, MD, on Clinical Minute to discuss a post hoc analysis of data from a phase 3 evaluation of the safety of netarsudil 0.02% compared to timolol 0.5%.
Meeting Updates
- AGS Annual Meeting | March 2–5, 2023; Live in Austin & Virtual
- YoungMD Connect Live | March 24–26, 2023; Live in Austin
- ASCRS Annual Meeting | May 5–8, 2023; Live in San Diego
- World Glaucoma Congress | June 28–July 1; Live in Rome
Survey Says: Procedure and IOL Selection
On a recent episode of “Survey Says” With I. Paul Singh, MD, a special edition of GT: The Podcast, Dr. Singh is joined by guests Shamil Patel, MD, MBA, and Manjool Shah, MD. The surgeons discuss how they would approach procedure and IOL selection for a real patient case, and later, they find out how their colleagues chose to proceed based on the results of a social media poll of GT’s audience.
Senior residents, fellows, and new practitioners (first 1–5 years in practice) are invited to participate in an in-person IOL & Biometry Master Class on Friday, March 24 at YoungMD Connect Live in Austin. Space is limited; to register, click here.
SpyGlass Pharma released 6-month data from a first-in-human glaucoma treatment trial showing that its drug delivery platform continues to demonstrate significant IOP lowering in patients with glaucoma or ocular hypertension, according to a company news release. The data were showcased by Malik Y. Kahook, MD, at the Glaucoma 360 New Horizons Forum in San Francisco. For more, click here.
